# CHINA NMPA REGULATIONS — AION-BRAIN

**Document Classification:** Chinese Regulatory Framework Guidance  
**Effective Date:** November 2025  
**Version:** 3.0  
**Jurisdiction:** People's Republic of China  
**Regulatory Body:** National Medical Products Administration (NMPA)  
**License:** Apache License 2.0 with NOTICE file  
**Document Governance:** Legal Engine v2.2 (Hallucination-Hardened Safeguards) + Legal Engine 2 v1.5 (Systematic Compliance Analysis) + Regulatory Engine v2.5 (Multi-Jurisdictional Intelligence)

---

## Document Authority

### 10-Role Genius Council Validation

This Chinese regulatory framework document was developed through multi-perspective analysis:

| Role | Contribution |
|------|--------------|
| General Counsel | Chinese regulatory classification architecture |
| Chief Compliance Officer | NMPA compliance verification |
| Regulatory Affairs Director | Chinese medical device regulation alignment |
| Privacy Officer | PIPL integration review |
| Healthcare Compliance Specialist | Chinese clinical use restrictions |
| Risk Management Officer | Chinese regulatory risk assessment |
| International Legal Counsel | China-specific compliance |
| IP Counsel | Chinese registration implications |
| Ethics Counsel | Chinese medical ethics considerations |
| Terms & Governance Specialist | User obligation clarity |

### Engine Integration

- **Legal Engine v2.2:** Citation integrity, Chinese regulation validation
- **Legal Engine 2 v1.5:** Systematic Chinese compliance gap analysis
- **Regulatory Engine v2.5:** Chinese regulatory intelligence

---

## Executive Summary

**AION-BRAIN is NOT an NMPA-registered medical device.** Users developing medical applications for China must independently ensure compliance with China's medical device regulations.

| Status | Classification |
|--------|---------------|
| **NMPA Classification** | Not a medical device |
| **Registration Certificate** | Not required |
| **Clinical Trial** | Not required |
| **NMPA Filing** | Not applicable |

---

## Chinese Regulatory Framework

### Key Regulations

| Regulation | Description |
|------------|-------------|
| **Administrative Measures for Medical Device Registration and Filing** | Core registration requirements |
| **Medical Device Classification Catalogue** | Classification criteria |
| **Administrative Measures for Software Medical Devices** | SaMD-specific requirements |

### Classification System

| Class | Risk Level | Regulatory Pathway | Examples |
|-------|-----------|-------------------|----------|
| **Class I** | Low | Filing with local MPDA | Basic medical tools |
| **Class II** | Moderate | Registration with provincial MPDA | Diagnostic equipment |
| **Class III** | High | Registration with NMPA | Life-support, implants |

### Software as Medical Device

```
CHINA SaMD CLASSIFICATION
═══════════════════════════════════════════════════════════════

Classification based on:
├─► Intended use
├─► Clinical decision impact
├─► Patient contact
└─► Risk level

AI-based medical software:
├─► Requires clinical trial for Class II/III
├─► Algorithm transparency requirements
├─► Data localization requirements
└─► Ongoing performance monitoring

═══════════════════════════════════════════════════════════════
AION-BRAIN: NOT CLASSIFIED — Research framework only
```

---

## User Responsibilities for Chinese Market

### If You Develop Chinese Medical Software

| Obligation | Description |
|------------|-------------|
| **Classification** | Determine NMPA classification |
| **Local Representative** | Required for foreign manufacturers |
| **Clinical Trial** | In-China clinical data often required |
| **Registration** | Obtain registration certificate |
| **Post-Market Surveillance** | Adverse event reporting |

---

## Data Protection

### Personal Information Protection Law (PIPL)

| Requirement | Application |
|-------------|-------------|
| **Consent** | Separate consent for sensitive data including health |
| **Data Localization** | Critical information infrastructure requirements |
| **Cross-Border Transfers** | Security assessments for data exports |
| **Data Processing Impact Assessment** | Required for sensitive data |

### Cybersecurity Law

| Requirement | Application |
|-------------|-------------|
| **Network Security** | Security measures for network operators |
| **Data Localization** | Important data must be stored in China |
| **Security Assessment** | Required for cross-border data transfers |

---

## Contact Information

**NMPA:** https://www.nmpa.gov.cn/

---

## Disclaimer

This document provides informational guidance only and is NOT regulatory advice. Engage qualified Chinese regulatory affairs professionals for specific guidance.

---

**Document Version:** 2.0  
**Effective Date:** November 2025  
**License:** Apache License 2.0

*This document is part of the AION-BRAIN Legal Framework*
